Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28639320 | 0.84 | CPA1 (0.51) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL25908577 | 0.84 | CPA1 (0.51) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL28327428 | 0.78 | SYK (0.45) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL28638619 | 0.78 | SYK (0.45) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL112859 | 0.78 | ALDH1A1 (0.64) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27373062 | 0.78 | ALDH1A1 (0.50) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL11263081 | 0.78 | ALDH1A1 (0.50) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27372568 | 0.78 | ALDH1A1 (0.50) | SLC15A1ALDH1A1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12292742 | 0.77 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7933968 | 0.77 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, MTPN | SLC15A1 3649/4885ALDH1A1 1231/4885MAPK1 3895/4885 |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYOF, MTPN | SLC15A1 3499/4885ALDH1A1 1386/4885MAPK1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.